|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Green D, Ponce de Leon S, Leon-Rodriguez E
and Sosa-Sanchez R: Adenocarcinoma of the stomach: Univariate and
multivariate analysis of factors associated with survival. Am J
Clin Oncol. 25:84–89. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Msika S, Benhamiche AM, Jouve JL, Rat P
and Faivre J: Prognostic factors after curative resection for
gastric cancer. A population-based study. Eur J Cancer. 36:390–396.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yasui W, Oue N, Aung PP, Matsumura S,
Shutoh M and Nakayama H: Molecular-pathological prognostic factors
of gastric cancer: a review. Gastric cancer. 8:86–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Allgayer H, Babic R, Gruetzner KU,
Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent
prognostic relevance in gastric cancer and is associated with the
expression of tumor-associated protease systems. J Clin Oncol.
18:2201–2209. 2000.PubMed/NCBI
|
|
6
|
Gaspar MJ, Arribas I, Coca MC and
Diez-Alonso M: Prognostic value of carcinoembryonic antigen, CA
19-9 and CA 72-4 in gastric carcinoma. Tumour biology. 22:318–322.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu MD, Dong L, Qi P, Weng WW, Shen XH, Ni
SJ, Huang D, Tan C, Sheng WQ, Zhou XY, et al: Pituitary
tumor-transforming gene-1 serves as an independent prognostic
biomarker for gastric cancer. Gastric cancer. Jan 28–2015.(Epub
ahead of print). View Article : Google Scholar
|
|
8
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: a new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varadhachary GR, Abbruzzese JL and Lenzi
R: Diagnostic strategies for unknown primary cancer. Cancer.
100:1776–1785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanaji N, Bandoh S, Fujita J, Ishii T,
Ishida T and Kubo A: Compensation of type I and type II cytokeratin
pools in lung cancer. Lung Cancer. 55:295–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moll R, Franke WW, Schiller DL, Geiger B
and Krepler R: The catalog of human cytokeratins: Patterns of
expression in normal epithelia, tumors and cultured cells. Cell.
31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edelman MJ, Hodgson L, Rosenblatt PY,
Christenson RH, Vokes EE, Wang X and Kratzke R: CYFRA 21-1 as a
prognostic and predictive marker in advanced non-small-cell lung
cancer in a prospective trial: CALGB 150304. J Thorac Oncol.
7:649–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fahmueller YN, Nagel D, Hoffmann RT,
Tatsch K, Jakobs T, Stieber P and Holdenrieder S: Predictive and
prognostic value of circulating nucleosomes and serum biomarkers in
patients with metastasized colorectal cancer undergoing selective
internal radiation therapy. BMC Cancer. 12:52012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holdenrieder S, von Pawel J, Dankelmann E,
Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K,
Hoffmann H, et al: Nucleosomes and CYFRA 21-1 indicate tumor
response after one cycle of chemotherapy in recurrent non-small
cell lung cancer. Lung Cancer. 63:128–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakata B, Takashima T, Ogawa Y, Ishikawa T
and Hirakawa K: Serum CYFRA 21-1 (cytokeratin-19 fragments) is a
useful tumour marker for detecting disease relapse and assessing
treatment efficacy in breast cancer. Br J Cancer. 91:873–878.
2004.PubMed/NCBI
|
|
16
|
Tang L and Han X: The urokinase
plasminogen activator system in breast cancer invasion and
metastasis. Biomed Pharmacother. 67:179–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baldini E, Sorrenti S, D'Armiento E, Di
Matteo FM, Catania A and Ulisse S: The urokinase plasminogen
activating system in thyroid cancer: Clinical implications. G Chir.
33:305–310. 2012.PubMed/NCBI
|
|
18
|
Andreasen PA, Kjoller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
20
|
Pellikainen JM, Ropponen KM, Kataja VV,
Kellokoski JK, Eskelinen MJ and Kosma VM: Expression of matrix
metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special
reference to activator protein-2, HER2, and prognosis. Clin Cancer
Res. 10:7621–7628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmalfeldt B, Prechtel D, Härting K,
Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W,
et al: Increased expression of matrix metalloproteinases (MMP)-2,
MMP-9, and the urokinase-type plasminogen activator is associated
with progression from benign to advanced ovarian cancer. Clin
Cancer Res. 7:2396–2404. 2001.PubMed/NCBI
|
|
22
|
Sullu Y, Demirag GG, Yildirim A, Karagoz F
and Kandemir B: Matrix metalloproteinase-2 (MMP-2) and MMP-9
expression in invasive ductal carcinoma of the breast. Pathol Res
Pract. 207:747–753. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arii S, Mise M, Harada T, Furutani M,
Ishigami S, Niwano M, Mizumoto M, Fukumoto M and Imamura M:
Overexpression of matrix metalloproteinase 9 gene in hepatocellular
carcinoma with invasive potential. Hepatology. 24:316–322. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang QW, Liu L, Chen R, Wei YQ, Li P, Shi
HS and Zhao YW: Matrix metalloproteinase-9 as a prognostic factor
in gastric cancer: A meta-analysis. Asian Pac J Cancer Prev.
13:2903–2908. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roxburgh CS and McMillan DC: Role of
systemic inflammatory response in predicting survival in patients
with primary operable cancer. Future Oncol. 6:149–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saito K and Kihara K: Role of C-reactive
protein in urological cancers: a useful biomarker for predicting
outcomes. Int J Urol. 20:161–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kleihues P and Sobin LH: World Health
Organization classification of tumors. Cancer. 88:2887. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
New York, NY: 2009.
|
|
29
|
Adachi Y, Yasuda K, Inomata M, Sato K,
Shiraishi N and Kitano S: Pathology and prognosis of gastric
carcinoma: Well versus poorly differentiated type. Cancer.
89:1418–1424. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siewert JR, Böttcher K, Stein HJ and Roder
JD: Relevant prognostic factors in gastric cancer: Ten-year results
of the German Gastric Cancer Study. Ann Surg. 228:449–461. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fujita Y, Terashima M, Hoshino Y, Ohtani
S, Kashimura S, Kanzaki N, Osuka F, Kogure M and Gotoh M: Detection
of cancer cells disseminated in bone marrow using real-time
quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with
gastric cancer. Gastric cancer. 9:308–314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo J, Yao F, Lou Y, Xu C, Xiao B, Zhou W,
Chen J, Hu Y and Liu Z: Detecting carcinoma cells in peripheral
blood of patients with hepatocellular carcinoma by immunomagnetic
beads and rt-PCR. J Clin Gastroenterol. 41:783–788. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koga T, Tokunaga E, Sumiyoshi Y, Oki E,
Oda S, Takahashi I, Kakeji Y, Baba H and Maehara Y: Detection of
circulating gastric cancer cells in peripheral blood using real
time quantitative RT-PCR. Hepatogastroenterology. 55:1131–1135.
2008.PubMed/NCBI
|
|
34
|
Zhao ZS, Li L, Wang HJ and Wang YY:
Expression and prognostic significance of CEACAM6, ITGB1, and CYR61
in peripheral blood of patients with gastric cancer. J Surg Oncol.
104:525–529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moll R, Löwe A, Laufer J and Franke WW:
Cytokeratin 20 in human carcinomas. A new histodiagnostic marker
detected by monoclonal antibodies. Am J Pathol. 140:427–447.
1992.PubMed/NCBI
|
|
36
|
Dossus L, Jimenez-Corona A, Romieu I,
Boutron-Ruault MC, Boutten A, Dupré T, Fagherazzi G,
Clavel-Chapelon F and Mesrine S: C-reactive protein and
postmenopausal breast cancer risk: Results from the E3N cohort
study. Cancer Causes Control. 25:533–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shimura T, Kitagawa M, Yamada T, Ebi M,
Mizoshita T, Tanida S, Kataoka H, Kamiya T and Joh T: C-reactive
protein is a potential prognostic factor for metastatic gastric
cancer. Anticancer Res. 32:491–496. 2012.PubMed/NCBI
|
|
38
|
Zhang SM, Lin J, Cook NR, Lee IM, Manson
JE, Buring JE and Ridker PM: C-reactive protein and risk of breast
cancer. J Natl Cancer Inst. 99:890–894. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kitagawa M, Shimura T, Yamada T, Itoh K,
Hasegawa C and Kawai T: C-reactive protein as an independent
prognostic factor for metastatic gastric cancer. J Clin Oncol (ASCO
Meeting Abstracts). 31:1102013.
|
|
40
|
Nozoe T, Iguchi T, Adachi E, Matsukuma A
and Ezaki T: Preoperative elevation of serum C-reactive protein as
an independent prognostic indicator for gastric cancer. Surg Today.
41:510–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Woo Y, Hyung WJ, Obama K, Kim HI, Pak KH,
Son T and Noh SH: Elevated high-sensitivity C-reactive protein, a
marker of advanced stage gastric cancer and postgastrectomy disease
recurrence. J Surg Oncol. 105:405–409. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kaneko T, Konno H, Baba M, Tanaka T and
Nakamura S: Urokinase-type plasminogen activator expression
correlates with tumor angiogenesis and poor outcome in gastric
cancer. Cancer Sci. 94:43–49. 2003. View Article : Google Scholar : PubMed/NCBI
|
